Cameron Santoro

Older adults with advanced breast cancer need personalized treatment plans considering fitness, preferences, and potential limitations for optimal outcomes and quality of life.

Research suggests tofacitinib effectively treats alopecia areata (AA), particularly when used early for severe cases. This offers promising evidence for doctors to consider when making treatment plans for patients.

Posters suggest deuruxolitinib, a medication targeting specific cellular pathways, effectively promotes hair regrowth in patients with moderate to severe alopecia areata (AA) and results in minimal adverse events.

A large-scale study suggests increased light at night exposure is linked to a higher risk of breast cancer, particularly in Asian populations and women with estrogen receptor-positive tumors (ER+).

Baricitinib and other oral JAK inhibitors show promise as effective treatments for moderate-to-severe alopecia areata (AA), with fewer adverse effects compared with traditional options.

Early research suggests ozone therapy may fight breast cancer cells and lessen adverse effects for patients undergoing treatment, but more research is necessary.

A study in San Bernardino County found no increased risks of alopecia areata (AA) after the COVID-19 vaccination but suggests further research into potential geographic and gender-based factors.

A study of patients diagnosed with early breast cancer during the COVID-19 pandemic found that the public health crisis did not produce significant changes in or delays treatment, despite many women presenting with palpable tumors.

A study found baricitinib to be safe and effective for treating severe alopecia areata (AA) but expressed the need for more long-term trials to support these findings.

An expert survey using the eDelphi method pinpointed disease duration, treatment response, and mental health as crucial factors in a new multidimensional tool known as Alopecia Areata Severity and Morbidity Index (ASAMI), underlining the importance of personalized treatments for future research incorporating patient perspectives.

Multigene assays allow for patients to receive personalized breast cancer treatment by identifying promising therapeutic targets, which could improve patient clinical outcomes in the long term and help providers better understand tumor biology.

Women with alopecia areata (AA), especially those with severe symptoms and lower income, face significant financial burden managing the condition.

Sisters of women with high breast cancer risk share similar risk factors, including high polygenic scores, benign breast disease history, and denser breast tissue.

A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).

A Japanese study of alopecia areata (AA) found misalignment between patient and doctor perceptions of severity, limiting treatment options, and leading to dissatisfaction and unmet needs.

Swedish women with prior false-positive mammograms, particularly those aged 60 to 75 with prior biopsies and low density, show elevated breast cancer risk, necessitating closer monitoring and better screening.

New research explores T cells and their signaling pathways in alopecia areata (AA), highlighting promising drug targets for future treatment.

Non-Caucasian patients with breast cancer face common influences in surgical decision-making due to fear, misinformation, cultural factors, and power dynamics, highlighting the need for patient-centered surgical decision-making.

Research suggests moderate to vigorous physical activity may help improve cognitive function in breast cancer survivors who have undergone chemotherapy and developed cancer-related cognitive impairment (CRCI).

Meta-analysis results identify high and low associations of various comorbidities like vitamin D deficiencies, ocular diseases, among others in patients with alopecia areata (AA), to promptly manage and improve treatment outcomes.

Baricitinib was found to be an effective treatment for patchy alopecia areata (AA), in a retrospective study, with most patients experiencing hair regrowth after 4 to 16 weeks of treatment.

Topical treatments and minoxidil solutions were found to be the most effective, safe, and affordable first-line options for treating pediatric AA.

A study from China found that tofacitinib was an effective treatment for alopecia areata (AA), with most patients achieving complete or partial hair regrowth and experiencing tolerable side effects.

Registered dietitian, Molly Kimball, RD, CSSD, of Ochsner Health, navigates cultural identity in diet changes for long-term success, in an interview.

A survey of pediatric dermatologists revealed that topical corticosteroids are the most common first-line treatment for children with alopecia areata, regardless of age or hair loss severity.

Black women with alopecia often struggle between concealing their hair loss and protecting their fragile scalps, all while seeking to express their cultural identity and build self-confidence.

Molly Kimball, RD, CSSD, of Ochsner Health, advocates for sustainable changes to populations' everyday behaviors to make healthy choices easier and more culturally relevant.

A US study found alopecia areata (AA) is more common in non-White patients, likely due to underrepresentation in dermatology, leading to less consideration of AA as a diagnosis for non-White individuals.

Sidney (Beau) Raymond, MD, MMM, FACP, chief medical officer of Ochsner Health Network, believes that the health care system should focus on preventing illness and disease, rather than just treating them after they occur.